Why Is Replimune Stock Trading Lower On Monday?
On Monday, Replimune Group Inc. (NASDAQ:REPL) is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage.
Benzinga ·